SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "WFRF:(Verhoef Ellen) "

form:Search_simp_t: WFRF:(Verhoef Ellen)

  • navigation:Result_t 1-2 navigation:of_t 2
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  • Anund Vogel, Jonas, 1981-, et al. (creator_code:aut_t)
  • Co-Creation in Living Labs to Accelerate Innovation
  • 2020
  • record:In_t: Civil Engineering Research Journal. - Irvine California United States : Juniper Publishers. - 2575-8950. ; 10:1
  • swepub:Mat_article_t (swepub:level_scientificother_t)abstract
    • Innovation in the construction sector occurs as stepwise reconfigurations of subsystems, but sometimes the effect of many systems coincides and there is so called radical change. Stepwise reconfigurations of individual systems such as windows, insulation, and heat recovery systems have made it possible to heat buildings with preheated inlet air instead of water radiators. Thus, making building more sustainable, cheaper and resource-efficient; the potential for radical change has been achieved. The question is then why not every new building uses preheated inlet air? The reason is not the lack of innovation or new technologies. It is rather connected to malfunctioning structures related to incentives, collaboration, testing, and validation, resulting in norms and standards that aim to reproduce existing technologies, preferring incremental innovations over radical ones.This article argues that testbeds and Living Labs are a way to work on complex, multi-stakeholder and urgent problems in a co-creative way. In these labs there are possibilities to test technologies, in systems, in real buildings and cities. There are possibilities to follow-up, measure and adjust; to live, study, work and develop. The Living Labs have the potential of making new technologies standard to use in the course of years instead of decades and thus minimize unnecessary use of resources linked to the construction and use of buildings. In addition, it will help to make technologies more user-friendly, considering user needs, wishes and experiences, thus contributing to the effectiveness of the technologies developed and tested.
  •  
2.
  • Hollestelle, Antoinette, et al. (creator_code:aut_t)
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
  • 2016
  • record:In_t: Gynecologic Oncology. - : Elsevier BV. - 0090-8258 .- 1095-6859. ; 141:2, s. 386-401
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-2 navigation:of_t 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t